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The letter of Giebel et al. 1 shows that the frequency of the deleted KIR2DS4 variant (KIR1D) in absence of the intact membraneanchored KIR2DS4 n 001 gene was significantly increased in chronic myelogenous leukemia patients compared to their donors. 1 They propose that the absence of intact activating KIR2DS4 may decrease the activity of natural killer cells against chronic myelogenous leukemia. In our previous study published in leukemia, we could not observe any association between the activating killer cell immunoglobulin-like receptor (KIR) genes and leukemia. 2 In contrast, we found an increased frequency of specific inhibitory KIR-HLA class I interactions in different types of leukemia. 3 However, we did not distinguish between the fulllength and deleted forms of the activating KIR2DS4 gene. In this regard, subtyping of KIRs at higher resolution can be important, because allelic diversity has been shown to have functional consequences such as changing the specificity, expression level or truncating the KIR. All together, both findings [1] [2] [3] point out that the natural killer cell-mediated immune response against leukemic cells might be reduced. So, the observation of Giebel et al.
1 is very interesting and adds important information to the role of KIR polymorphism in the pathogenesis of leukemia. 4 Compared with the results published by Giebel et al.,
1 KIR1D is the predominant KIR2DS4 type in the Caucasian population. 5, 6 Moreover, it has been noted that populations with high KIR1D frequency would have a lower incidence of AA phenotype, because KIR2DS4 is the only activating KIR on the AA phenotype. Consequently, individuals who are homozygous for haplotype A and KIR1D will not have any functional activating KIR gene. 6, 7 Therefore, it would be interesting to know the actual percentage of chronic myelogenous leukemia patients who are homozygous for the A haplotype and KIR1D in the cohort of Giebel et al.
1
A minor comment on the study of Giebel et al.
1 is that the frequency of individuals having only KIR1D was very variable between the different donor groups being the lowest in the donors of the chronic myelogenous leukemia patients. The authors mentioned that the control group was composed of related and unrelated HLA-matched donors. They should have also stated the percentage of relatives in each donor group, because siblings have 25% change to have an identical KIR genotype. This can reduce the difference in frequency of KIR1D between patients and their donors. Finally, it would be of particular interest to analyze KIR1D in a second independent case-control group to further confirm this observation. Dr Verheyden and Dr Demanet 1 raised several interesting questions in their comment to our letter. 2 Following their suggestion, we additionally analyzed chronic myelogenous leukemia (CML) patients and their donors with regard to homozygosity for haplotype A and killer immunoglobuline-like receptor (KIR)1D to identify subjects lacking any functional activating KIR. In the respective groups, the frequencies were 25.8 and 16.1%. As this difference was not statistically significant, it may be hypothesized that the effect of activating KIRs is rather qualitative and restricted to KIR2DS4 while other activating KIRs do not appear to play a role. Indeed, the frequencies of KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5, and KIR3DS1 were similar among CML patients and their donors. As well, the median sum of all activating KIRs was comparable (data not shown).
S Verheyden and C Demanet
In our study, we used human leukocyte antigen (HLA)-matched bone marrow donors as a representative control group, considering that (i) HLA genotype is associated with the occurrence and the age-at-onset of CML 3, 4 and (ii) KIR-HLA ligand interactions appear to play a role in the pathogenesis of leukemia.
5 HLA-identical siblings constituted 32.3% of donors in a cohort of CML, 36.8% in acute myeloid leukemia and 33.3% in acute lymphoblastic leukemia (P ¼ NS). However, as suggested by Verheyden and Demanet, 1 we additionally looked at data available for the Polish population (I Nowak, E Majorczyk, P Kusnierczyk, unpublished data). Among 363 healthy individuals, 63.2% were KIR2DS4n001 À /KIR1D þ compared to 77.4% in our CML cohort (P ¼ 0.08).
We feel that our results on activating KIR2DS4 are complementary to those previously published by Verheyden et al., stressing the role of inhibitory KIRs. 5, 6 In both cases, there is rationale to verify the findings in large populations of patients with particular subtypes of leukemia. autografts are currently being tested to improve aggressive B-chronic lymphocytic leukemia control. Several trials have documented the difficulty of mobilizing HSC by granulocyte colony-stimulating factor after treatment with fludarabine (FDR), which is considered the most effective first-line treatment. This
